133 related articles for article (PubMed ID: 11334729)
1. The BRCA1 syndrome and other inherited breast or breast-ovarian cancers in a Norwegian prospective series.
Møller P; Borg A; Heimdal K; Apold J; Vallon-Christersson J; Hovig E; Maehle L; ;
Eur J Cancer; 2001 May; 37(8):1027-32. PubMed ID: 11334729
[TBL] [Abstract][Full Text] [Related]
2. BRCA1 1675delA and 1135insA account for one third of Norwegian familial breast-ovarian cancer and are associated with later disease onset than less frequent mutations.
Borg A; Dørum A; Heimdal K; Maehle L; Hovig E; Møller P
Dis Markers; 1999 Oct; 15(1-3):79-84. PubMed ID: 10595257
[TBL] [Abstract][Full Text] [Related]
3. Histology of prophylactically removed ovaries from BRCA1 and BRCA2 mutation carriers compared with noncarriers in hereditary breast ovarian cancer syndrome kindreds.
Casey MJ; Bewtra C; Hoehne LL; Tatpati AD; Lynch HT; Watson P
Gynecol Oncol; 2000 Sep; 78(3 Pt 1):278-87. PubMed ID: 10985881
[TBL] [Abstract][Full Text] [Related]
4. BRCA1 and BRCA2 mutations among Finnish ovarian carcinoma families.
Sarantaus L; Auranen A; Nevanlinna H
Int J Oncol; 2001 Apr; 18(4):831-5. PubMed ID: 11251181
[TBL] [Abstract][Full Text] [Related]
5. Prevalence of founder BRCA1 and BRCA2 mutations among breast and ovarian cancer patients in Hungary.
Van Der Looij M; Szabo C; Besznyak I; Liszka G; Csokay B; Pulay T; Toth J; Devilee P; King MC; Olah E
Int J Cancer; 2000 Jun; 86(5):737-40. PubMed ID: 10797299
[TBL] [Abstract][Full Text] [Related]
6. A high occurrence of BRCA1 and BRCA2 mutations among Czech hereditary breast and breast-ovarian cancer families.
Machácková E; Foretová L; Navrátilová M; Valík D; Claes K; Messiaen L
Cas Lek Cesk; 2000 Oct; 139(20):635-7. PubMed ID: 11192759
[TBL] [Abstract][Full Text] [Related]
7. Pathology of familial breast cancer: differences between breast cancers in carriers of BRCA1 or BRCA2 mutations and sporadic cases. Breast Cancer Linkage Consortium.
Lancet; 1997 May; 349(9064):1505-10. PubMed ID: 9167459
[TBL] [Abstract][Full Text] [Related]
8. High frequency of recurrent mutations in BRCA1 and BRCA2 genes in Polish families with breast and ovarian cancer.
Grzybowska E; Zientek H; Jasinska A; Rusin M; Kozlowski P; Sobczak K; Sikorska A; Kwiatkowska E; Gorniak L; Kalinowska E; Utracka-Hutka B; Wloch J; Chmielik E; Krzyzosiak WJ
Hum Mutat; 2000 Dec; 16(6):482-90. PubMed ID: 11102977
[TBL] [Abstract][Full Text] [Related]
9. Prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers.
Rebbeck TR
J Clin Oncol; 2000 Nov; 18(21 Suppl):100S-3S. PubMed ID: 11060335
[TBL] [Abstract][Full Text] [Related]
10. Inherited susceptibility to breast and ovarian cancer.
Diamond TM; Sutphen R; Tabano M; Fiorica J
Curr Opin Obstet Gynecol; 1998 Feb; 10(1):3-8. PubMed ID: 9484622
[TBL] [Abstract][Full Text] [Related]
11. Three per cent of Norwegian ovarian cancers are caused by BRCA1 1675delA or 1135insA.
Dørum A; Hovig E; Tropé C; Inganas M; Møller P
Eur J Cancer; 1999 May; 35(5):779-81. PubMed ID: 10505039
[TBL] [Abstract][Full Text] [Related]
12. BRCA1 and BRCA2 genes: role in hereditary breast and ovarian cancer in Italy.
Santarosa M; Dolcetti R; Magri MD; Crivellari D; Tibiletti MG; Gallo A; Tumolo S; Della Puppa L; Furlan D; Boiocchi M; Viel A
Int J Cancer; 1999 Sep; 83(1):5-9. PubMed ID: 10449599
[TBL] [Abstract][Full Text] [Related]
13. BRCA1 and BRCA2 mutation status and cancer family history of Danish women affected with multifocal or bilateral breast cancer at a young age.
Bergthorsson JT; Ejlertsen B; Olsen JH; Borg A; Nielsen KV; Barkardottir RB; Klausen S; Mouridsen HT; Winther K; Fenger K; Niebuhr A; Harboe TL; Niebuhr E
J Med Genet; 2001 Jun; 38(6):361-8. PubMed ID: 11389159
[TBL] [Abstract][Full Text] [Related]
14. Intra-abdominal carcinomatosis after prophylactic oophorectomy in women of hereditary breast ovarian cancer syndrome kindreds associated with BRCA1 and BRCA2 mutations.
Casey MJ; Synder C; Bewtra C; Narod SA; Watson P; Lynch HT
Gynecol Oncol; 2005 May; 97(2):457-67. PubMed ID: 15863145
[TBL] [Abstract][Full Text] [Related]
15. Germline mutations in BRCA1 and BRCA2 in breast-ovarian families from a breast cancer risk evaluation clinic.
Martin AM; Blackwood MA; Antin-Ozerkis D; Shih HA; Calzone K; Colligon TA; Seal S; Collins N; Stratton MR; Weber BL; Nathanson KL
J Clin Oncol; 2001 Apr; 19(8):2247-53. PubMed ID: 11304778
[TBL] [Abstract][Full Text] [Related]
16. The Norwegian founder mutations in BRCA1: high penetrance confirmed in an incident cancer series and differences observed in the risk of ovarian cancer.
Heimdal K; Maehle L; Apold J; Pedersen JC; Møller P
Eur J Cancer; 2003 Oct; 39(15):2205-13. PubMed ID: 14522380
[TBL] [Abstract][Full Text] [Related]
17. BRCA1, BRCA2, and hereditary nonpolyposis colorectal cancer gene mutations in an unselected ovarian cancer population: relationship to family history and implications for genetic testing.
Rubin SC; Blackwood MA; Bandera C; Behbakht K; Benjamin I; Rebbeck TR; Boyd J
Am J Obstet Gynecol; 1998 Apr; 178(4):670-7. PubMed ID: 9579428
[TBL] [Abstract][Full Text] [Related]
18. First BRCA1 and BRCA2 gene testing implemented in the health care system of Stockholm.
Arver B; Borg A; Lindblom A
Genet Test; 2001; 5(1):1-8. PubMed ID: 11336395
[TBL] [Abstract][Full Text] [Related]
19. Frequency of BRCA1 and BRCA2 germline mutations in Japanese breast cancer families.
Ikeda N; Miyoshi Y; Yoneda K; Shiba E; Sekihara Y; Kinoshita M; Noguchi S
Int J Cancer; 2001 Jan; 91(1):83-8. PubMed ID: 11149425
[TBL] [Abstract][Full Text] [Related]
20. Multiple founder effects and geographical clustering of BRCA1 and BRCA2 families in Finland.
Sarantaus L; Huusko P; Eerola H; Launonen V; Vehmanen P; Rapakko K; Gillanders E; Syrjäkoski K; Kainu T; Vahteristo P; Krahe R; Pääkkönen K; Hartikainen J; Blomqvist C; Löppönen T; Holli K; Ryynänen M; Bützow R; Borg A; Wasteson Arver B; Holmberg E; Mannermaa A; Kere J; Kallioniemi OP; Winqvist R; Nevanlinna H
Eur J Hum Genet; 2000 Oct; 8(10):757-63. PubMed ID: 11039575
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
